Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
The new generation conjugate trastuzumab deruxtecan (Т-DXd) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have previously received a drug regimen containing anti-HER2 targeted agents, as well as for the treatment of adult patien...
Saved in:
| Main Authors: | R. A. Murashko, S. V. Sharov, E. P. Chashnikova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-03-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01) -
Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01) -
Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01) -
Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study
by: Fangfang Duan, et al.
Published: (2025-07-01) -
HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)